1308OActivity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). (23rd October 2018) - Yao, J C; Strosberg, J; Fazio, N; Pavel, M E; Ruszniewski, P; Bergsland, E; Li, D; Tafuto, S; Raj, N; Campana, D; Hijioka, S; Raderer, M; et al.